I'm back to 1/7

I'm back to 1/7


This was originally published here, in French. We provide this translation for your convenience, practical aspects may differ where you live.

This postcard made my day!

I assume you feel a little better than with Stribild®, 7/7. No? Do you believe me now?

I'm back to 1/7, with Dual Therapy, this time!

I have, in view, the last beacon that validates 2/7 (50 mg DTG + 300 mg 3TC), Saturday and Sunday. This is the last beacon, at 6 months. After, the project is to move to 1/7: 100 mg DTG + 600 mg 3TC, on Saturday; With a blood test on Saturday, if not on Friday, it suits me just as well...

For the average Joe-in-the-street, the 2/7 (DTG + 3TC), should be doable... We will see in a few weeks ... Especially since I already validated 4 months.

But, well ... I have lived for a long time with Leibowitch's 1/7 (1 NNTI + 3 INTI), and, there is just one thing to say: this 1/7 works Great! So, I'm going to be a little ahead of the call, and I've already started 1/7 (100 mg DTG (crunched or broken, with a meal) + 600 mg 3TC) since last Saturday.

I plan to try, once again, at 1/30! I say: once again at 1/30 ...

If you have 100% success, you have overdosed!

In alleviation, a basic principle: if at x / 7 an clinician-experimentalist has a perfect result, at least equal to that of the Septists (7/7), it is because she lacked ambition.

Having excellent results (cf Hocqueloux or Reynes) makes it possible to publish a good paper; It is also necessary to remain on a plateau, to ensure that it is sustainable.

But why the hell stop there ???

Even French guidelines authorizes the 4/7, whereas Tivicay® Monotherapy, will, at most, be open only to those who have avoided the Achilles Heel: the picture is clear:

First ICCARRE, second the Bi / mono of Tivicay®

First choice: the short cycle (ICCARRE), ideally 1/7
Second choice (for the anxious, forgetfuls or mutated viruses): Bi Tivicay® + 3TC. With possible extension, with some reservations (in particular because of Achille's Heel, which is present in 50% of failures, in BMM + P), to DTG as monotherapy (including, I know some pionners, in 4/7...)

But hey, I'm eligible for the Short Cycle, especially at 1/7, which I have experienced well enough.

Why the hell did I bother to leave Leibowitch's Short Cycle? The availability of DTG! Elementary, my dear Watson!

It was well worth trying! Among the disadvantages, a small depressive trend, strong in some, and that, we did not know say too much ...

As far as I am concerned, therefore, 7/7 with DTG, it will be a NO GO.

I used DTG 12.5 mg (1/4 of a pill, 7/7), for 6 months, it worked, thank you, but my first choice is the short cycle! And not the basic 4/7, please!

Exploring the formulas based on DTG will have allowed me to:
- better understand it
- explain, with full knowledge of the facts, to those many readers eager for this formula
- rethink, simplify, extend my Leibowitchian formula
- make new friends

Message to Leibowitch's Formula nostalgics: there is a Leibowitch before, an epiphany (Eureka!) Leibowitch and also a post-Leibowitchian future, which will see his hopes come true.

In the coming months, I will address two barely touched subjects:

ICCARRE, is a possibility for remission ICCARRE is a possibility for eradication

I also want to discuss the BIOSANTECH vaccine: the results are poorly presented, but with an ICCARRIAN perspective, it is potentially a killer.

I will also help defuse an unnecessary controversy, which runs among ICCARRIANS: ICCARRE is, certainly, a fight against overmedication (which Prep is not, obviously). It is above all one of the tools for eradication (PreP too, if it is affordable): Me, I am in FAVOR of PreP: see my Practical Guide PreP!

That is what is coming up, I will explain my argument later.

I measured my Eclipse: almost 1 month (but not 1 month ...), I kind of feel how to handle this.

With an Eclipse measured almost 1 month, I am an average patient: the average in recent studies shows it being 14-21 days, on average, knowing that it is in a Septist context, ie the most idiotic there is.

Post-Copernican science opens up to the world with a prediction, realized by the Eclipse. Yes the earth is round and No, the Australians do not fall out!

Eclipse! Eclipse! Good Lord!

Bring our sun back! Mr Farinelli (youtu.be/rqNrPV_3PpY)




This was originally published here, in French. We provide this translation for your convenience, practical aspects may differ where you live.

French guidelines authorize 4/7

By Charles-Edouard!

This was originally published here, in French. We provide this translate for your convenience, practical aspects may differ where you live.

In memoriam to Greg, a fighter who passed away in Jan. 2017, and had written:

Farewell, friend ... Overdose for a pathology impairs the treatment of others. Overdose of Tritherapies ... How many deaths?

Morlat capitulates! You didn't know ??

In France, the 'experts' report serves as guidelines, is written under the auspices of ANRS (and bears the name of its main author, Pr. Morlat: It has become 'A Confederacy of Dunces', a kind of biblical vademecum. Cite it and you are left alone, but if it is not in there, you are doomed...

This is the dung of the mind, but as it is worse elsewhere, we have to bear with it...

As early as 2016, it is known that the famous Morlat report will authorize ICCARRE 4/7; See my post here. This is presented at SFLS (Oct. 2016, p.17)

Well, since it's announced, we wait for the final text, so to share a laugh ...

Written in Nov. 2016, but online in Jan. 2017: no one dares talk about it ... You could look for it forever... It is well hidden in the bottom of a drawer: it is here! Lucky You! Now, you know about it.

How can traitor media be confounded?

The Morlat report aims at being a consensus ... This is not the case: cf the controversy by Pr. RAFFI ... It is the convergence of interests, of those who write it (we will come back to this!)

We can stand the lack of credibility, under the auspices of the ANRS, for a short while... At one point, they have to throw in the towel ...

The (bribed?) media-enemies of ICCARRE are defeated: their silence is deafening!

As usual, this is simple: you list your favorite media and you mark the date when the information is on their ticker. It speaks volumes!

Victory: Decrease in the number of days of treatment: Discontinuous

Full Victory! Then, admit the whole truth!

Victory that they would like to hide, for you will have noticed the trick: there is no mention of the FAUCY-DYBUL, FOTO, or ICCARRE trials: they would have to admit an enormous and reprehensible delay!

And Dr. Faucy and Dybul (trial NCT00339456 in 2010), Dr. Cal Cohen (FOTO in 2004) and Dr. J. Leibowitch (ICCARRE as early as 2010) ?? Do they suck??? Or are they the marker of your guilty denial?

Since you can consider 4/7 under conditions similar to those of the studies carried out, why not learn about all these studies?... No?

The simplest way is the Practical Guide. You will see immediately if you can consider be included in case by case. Rest assured! 90% of patients are eligible: you are most likely one of these cases ...

Otherwise, you will still have Tivicay® monotherapy, which I must tell you, at first sight of the DOMONO trial (PDF here), it is not encouraging, except if you take into account the selection algorithm. As a precautionary measure, Tivicay® + Lamivudine combination therapy is interesting, even if you have not been able to avoid the Achille's Heel Trojan Horse.

Good Weekend and good fuck!


This was originally published here, in French. We provide this translate for your convenience, practical aspects may differ where you live.

Trials vs Real Life

This was originally published here, in French. For your convenience, we provide this translation. Practical aspects may differ where you live.

Is real life different from trials?

by Charles-Edouard! (in bad mood...)

One of our readers testifies here, Feb. 24. 2017:

Thank you notes are my only reward! Thanks to you too ...

We will soon get to DOMONO, and its mixed results, having in mind the BMM cohort (Barcelona, ​​Montreal, Munich), whose results, after use of a selection algorithm are very good.

Why is true practice so different from 'science'?

Following the excellent presentation by J. Blanco at CROI 2017, the attack is cheerfully applauded. As the controversy can not be substatiated (monotherapy works for selected patients), lobbying focuses on the form. This is waged by Dr Joel Gallant, adored by web readers (althought this is disputable as Joel Gallant serves as a paid consultant/scientific advisor to Bristol–Myers Squibb, Gilead Sciences, Merck & Co., Theratechnologies and ViiV Healthcare/Glaxo-SmithKline) .

The charge is against DOLUMONO. Read the original article by Dr. Celia Oldenbüttel (photo opposite, abstract here): read, re-read, it required a motivated consultant to find a fly in the ointment ... Gallant lends his name and bankable e-reputation. (I had been fooled myself, but no more!). Grrr !! Hang on, here is the "argument" (cf article):
In a nutshell, Dr. Oldenbuttel would have evaded her prior authorization obligations, offered individualized care, but to many patients, so to get a mini trial, surreptitiousl, and get authorizations afterwards.

Bad faith, insinuations: beware of fakes!

The blame is extended to the other groups. Dr. Gallant even includes a factual error:
This is wrong !: the article by Dr. C. Gubavu [cf Hocqueloux, Orléans] states:
Dr. Gallant makes use of a (questionnable) US practice to create a misconduct by people merely enforcing their national regulations. Dr. Oldenbuttel measures GGT, CD4, CD8, lipids at the switch, that US doctors would supossedly not do: he sees the mark of a human experiment! My doctor does this tests, and with frequent follow-up. Who will blame Oldenbuettel? On the other hand, what do you think of those who do not ask for a complete panel and repeated blood draws, during a switch.

Dr. J. Blanco (opposite) explains why he makes this proposal to a patient, in front of him, with multiple failures. In a similar situation, what does Dr. Gallant do? Hmmm ??? Yet another switch with TRItherapy, then another TRItherapy, yet another TRItherapy, until the exhausted patient becomes 'lost to follow-up' (i.e. a cessation of treatment)?

Patients who have been (poorly?) treated badly with orthodox and abusive treatment take a leave with resulting health and epidemic damage. Guilt of US doctors, their standardized and ill-tolerated offering! They can escape legally (even ethically) but not morally. At least, Europeans have a suppression rate of 90%, where the US hardly gets to 50%! This kind of (sponsored?) lecturing is hard to swallow!

abusive nit-picking, "the argument" is spinned to commercial argumentation

The Germans overdo it: their technicality is unchallenged. The invisible, capitalist, hand exposes its voracious capture pattern: delay innovative trials, entrust them to the sacrosanct market players, and boo those who still practice their medical art with patients at heart.

J. Leibowitch, who contributed to the discovery of the virus, treatment, and alleviation much more than poor Dr. Gallant, was having dogs set on him, to the delight of the Great Capital.

Except that ... Except that ... The ANRS-4D trial , which was aimed at buying time and invalidating ICCARRE came back right on: ZERO intrinsic failure. Dr. Gallant knows how to find a fly on Dr. Oldenbuttel's ointment, but (how surprising!)> never mentions ICCARRE ...

The trial confirmed Leibowitch, who, for ICCARRE, had all necessary clearings. There is an exact match (ZERO intrinsic failure!) between the innovative team, and the formal ANRS test.

In Tivicay® mono it is the opposite: the BMM cohort, after proper screening (no Achille's heel, no poor compliance, nor initial viremia) gives good results. DOMONO, a randomized, inclusive trial, is a mixed success. A bit like IP monotherapy, authorized in France (on a case by case basis), and catastrophic in the MOBIDIP trial ...

Why does DOMONO leads to an interpretation opposite to that of BMM?

First, patients cheat ... They cheated in ANRS-4D, they cheated here too. The trial is in Amsterdam ... Where a high cheat rate and a 'I give the investigator the answer that pleases ...' effect has been reported. This is amplified by the linguistic problem identified here.
Dr. Vries-Sluijs comments (source):

Now, DOMONO is a cheater's realm and investigators credulity paradise !

Please explain how vL can go up with a perfect observance (sic) and without mutations of resistance (sic), yes! Please explain! On the other hand, patients who do not take their medicine and swallow 5 pills, the day before the blood test, that, I can understand!

In real life: ICCARRE

Many patients succeed in the Tivicay® mono: they are happy!

The price to pay for a safer Tivicay® monotherapy is not too hight:
- try, using a selective algorithm, the risk being low, and the harm null, and / or
- strengthen with Lamivudine (or Rilpivirine, should you prefer)

Many do not understand the Eclipse ... It's a pity! What can we do?

Eclipse is the necessary counterpart to chronicity. Your DNA is modified and now includes the recipe for apple pie [i.e. Of the virus ...]: it is not because your DNA has the recipe of the apple pie, that it begins to make apple pies like crazy!

The best solution: ICCARRE, and, the best ICCARRE is 1/7!

There, you have the choice between Leibowitch's patented formula or try to integrate Dolutegravir in your strategy (that is to say in 7/7, 4/7 or 1/7)

As far as I am concerned, both strategies worked very well. Then the little piss, the sold, the corrupt who sell their soup under cover of ethical concern, it disgusts me.

ICCARRE is good and above all ICCARRE is a tool for eradication ...

Note April 16: more fun? Try: How to make a clinical trial say whatever you want
And also more to come about Dr Joel. Gallant's own ethical issues : stay tuned

Good Weekend and good Fuck


This was originally published here, in French. For your convenience, we provide this translation. Practical aspects may differ where you live.

Ten green bottle

Ten green bottles hanging on the wall

... and if one green bottle should accidentally fall there'll be nine green bottles hanging on the wall


This was originally published here, in French. For your convenience, we provide this translation. Practical aspects may differ where you live.

Breaking News, 28/02: the results of DOMONO, here soon with exclusive data! ...

This blog is dedicated to the once-weekly, our choice, and, our title! Many reject it, out of ignorance; others are not eligible: Tivicay ® Monotherapy is a less prefered alternative. We discuss it, with some reluctence, so that relief is open to all.

Would be so easy to throw out monotherapy with the bathwater. Ah! ... I would so much like to be paid to applaude as soon as one of the ennemy lashes out at des-escalation. Ah! That would be easy! one alarmist presentation of DOMONO and, quick, we throw the mono-Tivicay ® to the pits ... Pff ... So naive!

Make no mistake: there will always be patients or practitioners to consider Tivicay® Monotherapy. Always. In the ICCARRE perspective of ours, they are wrong! Because ICCARRE (1/7) is better choice.

But being uninterested in either, is even more stupid! How many times have I wanted to force feed, with Tritherapy, the throat of those cheerleaders quacks!

Better try to understand how to use it right ...

As in "the ten green bootles", there is a method, an algorithm and ... and broken glass.

Achilles' Heel is no fad!

The Achilles heel? See this post ... Pr. Katlama opens a hypothesis to criticism and the general public; Then I am told that I am delusional ... Bullshit!

Dr. Celia Oldenbuttelle described in Antiviral Therapy, the first non-Achilles' Heel failure. She cares to specify:

If Dr. Celia Oldenbuttel cares to describe, with so many details, her counter-example, it shows that she gives credit to Katlama's hypothesis.

Dr. José Blanco, in his presentation to CROI 2017, will do the same (see below). So Katlama's theory, probably necessary, probably not sufficient, is taken seriously in Paris, Barcelona and Munich. This is not a Charles Edward's fad. Try to invalidate the hypothesis! Try it and publish! Get us entertained!

Barcelona, ​​Montreal and Munich

Let us reward the self-abnegation of forerunners! How? By learning from their experience ... For Oldenbuttel, it is viable for selected (sorted) patients. Dr. Blanco adds together Barcelona, ​​Montreal and Munich: 122 monotherapies. Let's look at the effect of a sorting algorithm on actual success.

And now, we're going to pop those green bottles hanging on the wall, one by one, until last!

First algorithmic rule: exclude the "Achille's heel" (= Trojan horse): They are not entitled to it (perhaps wrongly, but well ...).

Bing! Bing! Bing! Bing! Bing! Bing! We blow up SIX! 6 tell us how to avoid their mishaps. That is more than half!

Second algorithmic rule, mandatory for de-escalation: NIET to the forgetful. They give as much ammunition to the consulting fees fed enemy. By escaping the overdose, they plunge others into it!

TWO less! 50% and 88% compliance (overestimated, be sure...) is unacceptable!

Third algorithmic rule: we exclude from the analysis patients whose VL is detectable at inclusion! Should we exclude them from this strategy? That is another question; Exclude them from the analysis: yes ... (as for ANRS-4D or any formal trial).

Then there are 3 failures, over more than a hundred. And there is no dosage for compliance. Remember, before analysis of dosages, there was also 3% failure in ANRS-4D.

One of them perseveres, with courage (maybe he knew what to expect) and re-suppresses (<37) always in monotherapy. No dosage, nothing ... A failure? Not for him: he is happy, happy, happy. Is he the only one? No, two other patients take the same path while remaining under Tivicay ® mono! And the despised denigrators look very silly!

So, it is true, there are 2 ... Let 1, 2 or 3%. With viremia so small that it can be treated the first TRI at hand even to return to something lighter, and, consider the 4/7, which in our eyes was a better strategy. Hopefully they will understand!

No! The Tivicay ® mono is not the loser here!

The loser is the poor patient who, in maintenance, remains hooked, not matter what, to her shock TRItherapy, as useless as dangerous. And in the head quarters, they enjoy their cigars...

Indeed, the control group (bi and tritherapies, study in progress), has 6-7% failure!

As a conclusion, Tivicay® monotherapy, in maintenance, with careful selection of patients, is, as Dr. Oldenbuttelle says, a safe and effective strategy of de-escalation, in undetectable selected patients ...

Let's keep this in mind because DOMONO is going to be another hurdle!

Reminder: 95% of patients are overmedicated


This was originally published here, in French. For your convenience, we provide this translation. Practical aspects may differ where you live.

Lamivudine to the rescue

By Charles-Edouard!

This paper was originally published here, in French. We provide this translation for your convenience. Some practical aspects may differ where you live.

Breaking News, 18/02: the results of DOMONO, here soon with exclusive data! ...

Somes news from Lionel, in La Reunion, under Triumeq® 1/7 (once weekly)

It works, it works !!! And here, it does not surprise us at all! Good Job!

As far as I am concerned, MiniDolu (Tivicay ® 1/4 of daily cachet) worked well (6 months) but I prefer to reinforce, with that little Lamivudine, not unfriendly at all; For the time being: 50 mg of Tivicay® (DTG) + 300 mg of Lamivudine (3TC), Saturday and Sunday, with the goal of concentrating all on Sundays.

It is a bit like those taking Triumeq ® in 1/7 (DTG 50 mg + Lamivudine 300mg + Abacavir 600mg (!)), certainly, but without the Abacavir! ...

Easier to procure than the proven Leibowitch formula (quadrithapy, 1/7, once weekly: 1 NNRTI + 3 NRTI)

Lamivudine, the discreet star of successful trials

Lamivudine is a generic antiretroviral (and antiviral). Its copy fluorinated version is Emtricitabine; It's the same ... The manufacturers continue to feed themselves with crazy $$$, for a classic, now in public domain.

It is reputated innocent ... Reputation probably not well-substantiated, inasmuch as almost everyone takes Lamivudine (or its alter-ego) one can not differentiate: it is impossible to distinguish its toxicity from that imputed to the Virus or to treatment in general.

It has shown up in several recent trials including: Gardel, Paddle, Lamidol, Dual ... Monotherapies (from Tivicay ® or antiproteases) are satisfactory, but are experiencing some failures. Conversely, let's add the innocent (and inexpensive) Lamivudine, and here you are with a quasi-general success.

Adios to 3TC Resistance (M184V)

Like Videx, its intrinsic power is low. 1 Log as monotherapy, with development of mutation at position 184. The mutated virus remains rather sensitive (0.5 Log, env.), therefore, one finds it or her look-alike, within ALL conventional triple therapies: without exception: Atripla ®, Stribild® / Genvoya®, Eviplera®, Truvada® + X, Kivexa® + X, a lot of guys!

Some (surrealists) Researchers, had assessed its power contribution to 12% of TRI.

Most trials have patients without the M184V. Professor Reynes (DOLULAM) observes nevertheless that he has 10 patients (37%) with this mutation, and, it works for them too!

This is also true in MOBIDIP (see below). This is very good news for 'historical' patients: they should no longer be opposed the M184V to prevent them from lighter therapies.

PADDLE

Total success with DTG + 3TC, as frist line, by Dr. Cohen, in Buenos Aires. Tasty Anecdote: There was one patient with a positive viraemia, which should have been called 'virologic failure'. Contrary to our Parisian virologists, who would have stuffed him with tritherapy, good Dr. Cohen decides to persevere, and here he is rewarded with re-suppression.

Dr. Lanzafame does just as well with his Tivicay ® mono, as induction (9 patients published, and others soon to be ...)

LAMIDOL: success of DGT + 3TC maintenance

It is an ANRS trial, of maintenance, where 104 patients have been instructed to take Tivicay ® / Lamivudine, daily, and, there is only one intrinsic virological failure (ICCARRE + ANRS-4D = ZERO intrinsic failure on 190 patients!)

On the other hand, there are failures in DOMONO (maintenance with DTG alone), and there remains the vast question of the Achille's heel, for those who may be punished for taking Isentress ® , Stribild® / Genvoya®.

The price to pay to add Lamivudine, is not expensive at all. Especially since Abacavir or Tenofovir are thus definitely eliminated!

Those who continue to take tablets with 3 or 4 agents, with suspected cumulative toxicity (eg Triumeq®, Stribild® / Genvoya®), beyond the attack phase, are ignoring the progress of the pharmacopoeia and the clinic.

MOBIDIP: maintenance by IP / r + 3TC does better than IP / r

Despite Salpetriere's support, monotherapy under IP, in maintenance, does not attract many patients. The MOBIDIP test (ANRS 12286) probably shot it dead: the monotherapy arm had to be interrupted (too many virological failures), while the Bitherapy arm remains satisfactory.

Prof. François Raffi comments: A higher rate of success than IP/r monotherapy despite the presence of the M184V mutation. Indeed, 97 of the 137 patients in the IP/r + 3TC arm showed the M184V mutation (typical of 3TC resistance).

The conclusion is clear: maintenance with PI/r plus 3TC is associated with a high rate of success despite the presence of M184V whereas PI/r monotherapy can not be recommended.

You might be surprised to see the ANRS in this adventure. Doomed to fail ? Easy to say afterwards ... Here, too, I have repeatedly expressed the opinion that ICCARRE is a better plan!

Well ... At this point, my position is strengthened. MOBIDIP: death of IP Mono.

To go further, read The Magic of 3TC, on page 20.

Good Weekend and good fuck!


This paper was originally published here, in French. We provide this translation for your convenience. Some practical aspects may differ where you live.

2017 Darwin Day

2017 Darwin Day

This paper was originally published here, in French. We provide the google translation for your convenience. Proper translation will come soon. Some practical aspects may differ where you live.

From a persistent patient:



Tivicay ® monotherapy, once validated, invite to a 4/7 relief (mono Tivicay ®)

It is attractive and has a good balance between reducing toxicity, cost, discomfort, etc.

My MiniDolu experience (1/4 pill, 7/7) was fine, but I'm in small form, so I prefer to take more. The optimal weekly dosage, ballpark estimate, can be between 100 and 200 mg, in the context of my suspected interactions. I am trying 50 mg DTG + 300 mg 3TC, Saturday + Sunday; If it works (thus far, 4 months without VL uptake...), I will move on to 100 mg DTG + 600 mg 3TC on Sunday.

Tomorrow is Darwin Day!

Any aliviating patient safeguard: Drowning! misunderstood by Katlama, denied by American doctrinaires (creationists in by nature...), drowning is the lifeguard buoy that allows the unfortunate aliviating patient (if any ...).

Described by JACQUES LEIBOWITCH (his book How To end AIDS, PLON, or on the net):


Wild-type virus = sensitivity to all initial classes: Cool!

Well ... It does not happen in 5 minutes, so you should have a time reserve (1 year?); When one has entered the treatment early, then the time reserve is guaranteed: this is an argument in favor of early treatment; But who will promote it

Finally, we revisit Darwin, and so on, here are a few ressources:



In French: Anniversary Conference

The image resistance

The Origin of Species (audio-book) is a refutation of William Paley and his Natural Theology

Series

Richard Dawkins Christmas Conferences

And the man created the dog

Best of PZ Myers Arguments And Comebacks

In the news:

- Donald Trump - The price of the medicine: Le Monde and YouTube

- Genvoya authorized for a price decrease

- Lanzafame launches a semi-4/7

- DOMONO: complete results at the CROI

Good Day of Darwin and Good Stuff!

At-home VL

This paper was originally published here, in French. We provide the google translation for your convenience. Proper translation will come soon. Some practical aspects may differ where you live.

Immediate VL, without going to the lab ;-)

By Charles Edouard!

From one of our exotic correspondents:

In France also! No prescription needed to get a viral load; Approximately 60 Euros. The practical guide explains how to do this; At initiation of the Short Cycle, it is necessary to increase the VL frequency: month-1, month-2, month-4, month-6, etc.

Soon, VL at your fingertip ...

It may be possible to do a rapid viral load without going to the lab, according to a preliminary study published in scientific reports, followed by a press release. (poorly written); The full version is published by Nature: New pH-detecting semiconductor for the detection of HIV-1 viremia at the point of service

The researchers developed a computer chip and tested. A test amplifies HIV RNA in a small amount of blood and the results are converted into an electrical signal that can be read by a computer or a mobile device.
The entire process takes about 30 minutes.

The limit of detection is 1000 copies / mL: this may be sufficient (*) to ensure:
- there is no replication consecutive of resistance
- the intransmissibility of HIV (see initial study: RAKAI)
- a greater diffusion of the technique

(*): May be ... we will see at that time, we are not there yet ... In the future, we might get better stuff.

It is sufficient (*) for maintenance (ICCARRE ...), and also for optimal dosage analysis with Tivicay ® (DTG) (*).

Monitoring viral load is crucial to the success of HIV treatment. At the moment, testing often requires costly and complex equipment that can take a couple of days to produce a result. We have taken the job done by this equipment, which is the size of a large photocopier, and shrunk it down to a USB chip.

Dr. Cooke adds that "this technology, although in the early stages, could allow patients to monitor their level of virus in the same way that people with diabetes check their blood sugar levels."

Good ... It is not yet on the market ... Until then, VLs are done in the lab, with or without prescription, and the results via Internet!

Good Week-End and Good Fuck!


This paper was originally published here, in French. We provide the google translation for your convenience. Proper translation will come soon. Some practical aspects may differ where you live.

Welcome to 20...1/7

Welcome to 20...1/7
This paper was originally published here, in French. We provide the google translation for your convenience. Proper translation will come soon. Some practical aspects may differ where you live.

What should be monitored in 2017?
By Charles Edward!

This year will be in our favor: 1/7

Hello Charles-Edouard,
I tried on 3/7 and 2 consecutive days [Ndr: Triumeq®], but the effects are too heavy.
Even 2/7 spaced is already difficult.
So I will continue on Tuesday and Friday, and hope for the 1/7!
Good day and Happy New Year. Quartet

Announced by ANRS in July 2016, this very big trial of the 4/7 is announced for this beginning of the year. Especially since IAS 2017 will be held in Paris ... High visibility!

Morlat 2017?

The update of the dissensus consensus report is announced here by the SFLS: there will be sport!

Genvoya

Not allowed in 2016 (so de facto prohibited ...). Price negotiation is tricky ... Gilead does not lower his claims. Legitimate? What does it matter? The basic issue is the Trojan Horse: authorizing an agent suspected of AIDS-2, would be a decision of the same nature as the tainted blood scandal. No less ... So to follow closely!

The Achilles heel

Precaution: as long as the suspicion remains, stay away from Isentress ®, Stribild ® or Genvoya ®

DOMONO

The complete analysis of DOMONO is expected; We will see more clearly soon ... Bémol pending

Lanzafame

We expect new publications from the very creative Dr. Lanzafame.

The biithérapies

Let's talk about Tivicay®. ViiV is going to give it to heart joy and Les Bithérapies will conquer market share. This post from Dr. David Alain Wohl gives a foretaste of the upcoming commercial foot change. To conquer a market without destroying it, the soldier must be saved! We will follow with delight the maneuver ... It promises here

Sonigo at the party, Leibowitch too!

The duo Kupiec / Sonigo enjoyed a great consecration here. Finally! Sonigo? It was he who conceptualized the Eclipse, concretized by Leibowitch: it is very dear to us ... To follow, then ...

Trump and Big Pharma

Yes! Donald Trump promised to attack the price of the medoc caviars, it is at the minute 5: 20ici! With us, no denunciation of this type and yet! The scandal is doubled by a negligence on the price of generics: to follow!

Transparency

Doctors and patients require less opacity in clinical trials. A wonderful example is given to us by Chaffetz: it's delicious: his "Trust but verify" leads him to assign the FBI: to savor! We did not go to the end of the Cahuzac scandal and the corrupters. Corruption is like the Chernobyl cloud: it does not stop at the Border (moreover, there is no more, or so little): one must accept the idea that Exists and is prejudicial to us. The corporatist between us, therefore the Council of Order is the archaic symbol is harmful to us!

Social Security:

We must save the security! The alternative proposed (Fillon ...) is the insurance company. So costly, juicy, and unsuitable (see USA!). Already remembering where it comes from, where does the chronic deficit come from? (Cf Dr. Gérard Delépine, Even Professor Grimaldi is there, then!) The issue will be debated during the presidential election, Will also invite!

My freedom:

More rights and less Freedom: the quinquennium is contrasted. Freedom is attacked from every side: the Internet has become a tool of propaganda in the hands of the powerful:

Ask yourself a question, at the time of copying / pasting fast-made: this blog is unique in its content. Why unique?

Contribute! Comment on it! Likez! Share it!

Bah yes ... Do not spread relief to all, is to deprive them of a better treatment. So move a little!

In short ... of the TAF in perspective. Bon Week-End and Bonne Bourre!


This paper was originally published here, in French. We provide the google translation for your convenience. Proper translation will come soon. Some practical aspects may differ where you live.

2016 is over

2016 is over

Our take on 2016

by Charles-Edouard!
This paper was originally published here, in French. We provide this translation for your convenience. Some practical aspects may differ where you live.

This blog is a useful read, it was a good idea to move your ass!

The Achilles heel

Patients are interested by Tivicay ® monotherapy, as expected! If you had a failure with Stribild® / Genvoya® or Isentress® do not even risk it: it's in the red. Does the red zone extend to previous users of Stribild® / Genvoya® or Isentress® without failure? In a first approach (Katlama), this is a gray zone, dark gray ... With 20% of failures in this population, it is risky! For those who have never taken Isentress ® or Stribild ® / Genvoya ®, the risk is lower. Is it zero? We will see ... Especially since the Achille's Heel is written on the patient's DNA, therefore, can be transmitted.

Achille's Heel ... Achille's Heel ... Yes ... For those who have it, de facto, they are not at fault... We did not know ... It is the Fault to Noone. But this was before: now we know: For the newbies, it is no more an Achilles's Heel, but a Trojan Horse!

This inefficiency of Dolutegravir (mono) is either acquired, transmitted or innate.
Transmitted or innate, the patient or the doctor can do not nothing: it is an Achille's heel.
Acquired, it's not the same! Today we know ... And when they prescribe, it is knowingly! So it's a Trojan horse, a ruse...

Acquired Inefficiency Dolutegravir Syndrome: A.I.D.S. Yes ... All this affair is that of an underhanded attack of your natural barriers by an infiltrated agent, acquired by negligence. In its construction, it looks very much like a AIDS-2: letting in an agent that can render your barrier ineffective, natural for AIDS-1, pharmaceutical in case of a possible AIDS-2.

Not final at this point, it deserves full attention and preparedness.

Genvoya® NOT authorized! Surprise!

Genvoya® did not receive the final thumbs up from French Ministry, in 2016 ... It may surprise some... But not our readers who understood the 2 stumbling blocks, not just one, as it would be too easy to make believe.

Gilead communicates on the only pitfall that constitutes the weak level of the ASMR (additional medical service) (publication by HAS, French Health Authority).
Communication is not Information.

The price negotiation failed: if Gilead had lowered its claims, it would not have failed. It's a price negotiation. It fails, then, it's a little easy to put responsibility on the buyer, alone. There is always a good price where the buyer could accept. The economic committee is the only barrier against voracity: it is the only one ... Apart from a possible Trojan horse, within it, it defends us. With the transparency commission (SunShine Act like), it is still more difficult than before to place your 'buddies' ... The new system (Xavier Bertrand) defends itself better.

If HAS is followed, the prescription should not be considered as a continuation prescription after Stribild® / Genvoya® or Isentress®. And only in that context! How to give a marketing authorization, in the broad sense, without associating an effective restriction?

For now, the problem is temporarily solved: there is no marketing authorization ... If Gilead manages to remove obstacle number 1 (the weak ASMR), how will our administrative authorities react? How will they protect the naive patient? Well, we'll see in 2017.

For now, the institutional barrier has played its role.

Minidolu: it worked

If interested in Tivicay® monotherapy, you can wait for a clarification.

For the more adventurous, those who have successfully used Tivicay® monotherapy (1 year validation), they can consider the ICCARRE reduction or reduce the dose.

Me, I like Minidolu, it worked well (validation over 6 months) ...

I also like the Short Cycle... We will see in 2017 (in fact I already started a new thing ... Tivicay® + Lamivudine (DTG + 3TC) on Saturday and Sunday.)

Total Success for 4/7 (ANRS-4D)

For the 96 patients who were eligible and who followed, without cheating, the protocol, the success has been total: zero failure.

This proves that Leibowitch did not deceive us ... well ... ANRS goes full scale: better late than never, but so much time wasted! And suffering inflicted! Not to mention the exorbitant cost! Ah, we'll do the counting! ANRS-4D: trial 600.000 Euros, annual savings 400.000 Euros: the best investment for our government!

By spending less, wisely, on can fill the deficit, maintained, of our Socialed Health and save it, without putting France on its knees, as proposed by F. Fillon.

The icing on the cake

Goodbye, sad clown! ... We won? Not sure! What a loss of time! A five-year period of which he only has one regret (keep well seated...): the false debate on citizenship. In the meantime, the 1.5 million additional unemployed will appreciate and will vote. Not so simple when you read the Fillon program for social security (kindly published by the Canard), and of which the Senate Channel has broadcasted the implementation project.
It's sure game! Finally, we have put behind us a casting error: the casting method is a real catastrophy: the primary is used to eliminate: remains the most idiot ... We have been fooled! Pffff ...

C'est la vie! Champagne!!!


This paper was originally published here, in French. We provide this translation for your convenience. Some practical aspects may differ where you live.

testimonies

testimonies
This paper was originally published here, in French. We provide the google translation for your convenience. Proper translation will come soon. Some practical aspects may differ where you live.

Some testimonials ...

By Charles Edouard!

Here we read the testimony by patient ZERO: video


Short-cycle (6/7, 5/7; / 4/7) has been explored since 2000 (approximately), in parallel (one could say competition), with other ideas (e.g. long cycles, Controlled long-term interruption, monotherapy, etc.). This strategy was explored by 2-3 doctors (Dr. Cal Cohen in the USA, Dr. Leibowitch in France).
There are many veterans of the Short-cycle ... And they are people of flesh and bones.

They have left us their testimony in the trials, which are as many certified testimonies, published under hospital control: eg. ANRS-4D: So it's not anecdotal.

They also testified (thank you!) ... The publisher offers a free excerpt:
http://www.pictorus.info/pdf/00_ExtraitICCARRE.pdf

And also: Alexandre Bergamini: who wrote Forsaken: An AIDS Memoir.

Among other testimonies, palmsprings describes:

Impose your luck! (*)

From our great friend, Myriam:
Hold on to your happiness! (*)

And from a pusillanimous Hugo...
... and goes to your risk. (*)

Dr. Jacques Leibowitch wrote:



66 patients at 2 days per week, out of 94, it is 2/3 of those who lighten, or 1 in 2 patients of this APHP hospital; And says here: I have fifteen patients to 1 day a week

To look at you, they will get accustomed

The film to be seen ... In his hospital in Brest, a pulmonologist discovers a direct link between suspicious deaths and the taking of a medicine marketed for 30 years, the Pick. From the isolation of the beginnings to the media explosion of the affair, the story inspired by the life of Irene Frachon is a battle of David against Goliath to finally see the truth triumph.

To see again: from the lie to the confessions return on the scandal Cahuzac

To follow in the news: ANRS launched a comparative trial, in the second line, (monotherapy-IP alone vs with Lamivudine), hence its name MOBIDIP (Mono or Bitherapy of Protease Inhibitor) Premature termination of IP Monotherapy (presentation in Glasgow, last month).

(*): This is a poetic emphasis, not a medical advice; It comes from ...

Impose your luck, shake your happiness and go to your risk. To look at you, they will become accustomed (René Char, 1950)


This paper was originally published here, in French. We provide the google translation for your convenience. Proper translation will come soon. Some practical aspects may differ where you live.